SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling